Maria Argyrou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maria Argyrou has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alexia Valassi
1st Radiology Department, National and Kapodistrian University of Athens, 115 28 Athens, Greece
2 shared publications - Maria Andreou
1st Radiology Department, National and Kapodistrian University of Athens, 115 28 Athens, Greece
2 shared publications - Maria Lyra
Universidade Federal de Pernambuco, Brasil
2 shared publications - A. Katsikatsou
Physics Department, Nuclear and Particle Physics Section University of Athens GR-15771 Athens Greece
1 shared publication I. Malamos
Physics Department, Nuclear and Particle Physics Section University of Athens GR-15771 Athens Greece
1 shared publication
Latest Publications
- Open Access
- 11 April 2013
- Published by Wiley in ISRN Molecular Imaging
- Vol. 2013, 1-6
Dosimetry and Therapeutic Ratios for Rhenium-186 HEDP
Rhenium-186 (Re-186) is a β-emitting radionuclide. Emitted β-particles have ranges up to 4.5 mm in tissue, capable of delivering high doses to skeletal regions of high Re-186 concentrations while sparing adjacent radiosensitive regions and thus making the irradiation well tolerated for the patient. Along with the β-emissions, γ-rays are emitted having an adequate energy for imaging during therapy and biodistribution assessment for patient-specific dosimetry calculations. The relatively short physical half-life combined with the β-emissions allows the delivery of relatively high activity rate for a short period of time in areas of concentration. This study is a short review concerning the palliative treatment of skeletal metastases using 186Re-HEDP. After presenting the dominant ways of 186Re production, special emphasis is given to dosimetry issues while the effect of palliation therapy can be evaluated through the comparison of the absorbed dose in metastatic lesion relatively to the normal bone region. Accurate dose estimation is required taking into account the anatomic individual difference of each patient. For this purpose a patient specific dosimetric model considering metastatic lesions as spherical nodules is introduced. In order to quantify in a representative way the results of palliation treatment, the concept of therapeutic ratios is analyzed.
- 11 April 2013
- Published by Wiley in ISRN Molecular Imaging
- Vol. 2013, 1-6
Open AccessDosimetry and Therapeutic Ratios for Rhenium-186 HEDP
Rhenium-186 (Re-186) is a β-emitting radionuclide. Emitted β-particles have ranges up to 4.5 mm in tissue, capable of delivering high doses to skeletal regions of high Re-186 concentrations while sparing adjacent radiosensitive regions and thus making the irradiation well tolerated for the patient. Along with the β-emissions, γ-rays are emitted having an adequate energy for imaging during therapy and biodistribution assessment for patient-specific dosimetry calculations. The relatively short physical half-life combined with the β-emissions allows the delivery of relatively high activity rate for a short period of time in areas of concentration. This study is a short review concerning the palliative treatment of skeletal metastases using 186Re-HEDP. After presenting the dominant ways of 186Re production, special emphasis is given to dosimetry issues while the effect of palliation therapy can be evaluated through the comparison of the absorbed dose in metastatic lesion relatively to the normal bone region. Accurate dose estimation is required taking into account the anatomic individual difference of each patient. For this purpose a patient specific dosimetric model considering metastatic lesions as spherical nodules is introduced. In order to quantify in a representative way the results of palliation treatment, the concept of therapeutic ratios is analyzed.
- Open Access
- 9 April 2013
- Published by Wiley in International Journal of Molecular Imaging
- Vol. 2013, 1-7
Rhenium-188 Production in Hospitals, by W-188/Re-188 Generator, for Easy Use in Radionuclide Therapy
Rhenium-188 (Re-188) is a high energy -emitting radioisotope obtained from the tungsten-188/rhenium-188 (W-188/Re-188) generator, which has shown utility for a variety of therapeutic applications in nuclear medicine, oncology, and interventional radiology/cardiology. Re-188 decay is accompanied by a 155 keV predominant energy -emission, which could be detected by -cameras, for imaging, biodistribution, or absorbed radiation dose studies. Its attractive physical properties and its potential low cost associated with a long-lived parent make it an interesting option for clinical use. The setup and daily use of W-188/Re-188 generator in hospital nuclear medicine departments are discussed in detail. The clinical efficacy, for several therapeutic applications, of a variety of Re-188-labeled agents is demonstrated. The high energy of the -emission of Re-188 is particularly well suited for effective penetration in solid tumours. Its total radiation dose delivered to tissues is comparable to other radionuclides used in therapy. Furthermore, radiation safety and shielding requirements are an important subject of matter. In the case of bone metastases treatment, therapeutic ratios are presented in order to describe the efficacy of Re-188 usage.
- 9 April 2013
- Published by Wiley in International Journal of Molecular Imaging
- Vol. 2013, 1-7
Open AccessRhenium-188 Production in Hospitals, by W-188/Re-188 Generator, for Easy Use in Radionuclide Therapy
Rhenium-188 (Re-188) is a high energy -emitting radioisotope obtained from the tungsten-188/rhenium-188 (W-188/Re-188) generator, which has shown utility for a variety of therapeutic applications in nuclear medicine, oncology, and interventional radiology/cardiology. Re-188 decay is accompanied by a 155 keV predominant energy -emission, which could be detected by -cameras, for imaging, biodistribution, or absorbed radiation dose studies. Its attractive physical properties and its potential low cost associated with a long-lived parent make it an interesting option for clinical use. The setup and daily use of W-188/Re-188 generator in hospital nuclear medicine departments are discussed in detail. The clinical efficacy, for several therapeutic applications, of a variety of Re-188-labeled agents is demonstrated. The high energy of the -emission of Re-188 is particularly well suited for effective penetration in solid tumours. Its total radiation dose delivered to tissues is comparable to other radionuclides used in therapy. Furthermore, radiation safety and shielding requirements are an important subject of matter. In the case of bone metastases treatment, therapeutic ratios are presented in order to describe the efficacy of Re-188 usage.
- Open Access
Refinements in Effective Potential Calculations in the MSSM
The one-loop effective potential is a powerful tool in studying the electroweak symmetry breaking of supersymmetric theories, whose precise calculation may have important phenomenological consequences. In this work, we are correctly treating the contribution of the Higgs sector to the effective potential and refine the radiative corrections to the Higgs mixing parameter $\mu$, which is known to affect greatly the supersymmetric spectrum. Working at the average stop scale to minimize the effect of the stop sector, we find additional corrections which can play a dominant role in the Focus Point region of the parameter space of the MSSM. The comparison of our results with those of the literature is discussed. We also discuss the gauge dependence of the effective potential and its effect on the $\mu$ parameter in analyses where this is determined from the 1-loop minimization conditions of the effective potential.Open AccessRefinements in Effective Potential Calculations in the MSSM
The one-loop effective potential is a powerful tool in studying the electroweak symmetry breaking of supersymmetric theories, whose precise calculation may have important phenomenological consequences. In this work, we are correctly treating the contribution of the Higgs sector to the effective potential and refine the radiative corrections to the Higgs mixing parameter $\mu$, which is known to affect greatly the supersymmetric spectrum. Working at the average stop scale to minimize the effect of the stop sector, we find additional corrections which can play a dominant role in the Focus Point region of the parameter space of the MSSM. The comparison of our results with those of the literature is discussed. We also discuss the gauge dependence of the effective potential and its effect on the $\mu$ parameter in analyses where this is determined from the 1-loop minimization conditions of the effective potential.